Key result
Coronary microvascular inflammation with endothelial dysfunction is a common denominator among HFpEF, obesity, and diabetes, and targeting this shared underlying process may improve outcomes.
Answers are grounded in this paper and cite their sources.
Targeting shared microvascular disease pathways in HFpEF patients with obesity or diabetes may offer novel therapeutic strategies to improve quality of life and outcomes.
Heart failure with preserved ejection fraction (HFpEF) is a major unmet medical need that is characterized by the presence of multiple cardiovascular and non-cardiovascular comorbidities. Foremost among these comorbidities are obesity and diabetes, which are not only risk factors for the development of HFpEF, but worsen symptoms and outcome. Coronary microvascular inflammation with endothelial dysfunction is a common denominator among HFpEF, obesity, and diabetes that likely explains at least in part the etiology of HFpEF and its synergistic relationship with obesity and diabetes. Thus, pharmacological strategies to supplement nitric oxide and subsequent cyclic guanosine monophosphate (cGMP)-protein kinase G (PKG) signaling may have therapeutic promise. Other potential approaches include exercise and lifestyle modifications, as well as targeting endothelial cell mineralocorticoid receptors, non-coding RNAs, sodium glucose transporter 2 inhibitors, and enhancers of natriuretic peptide protective NO-independent cGMP-initiated and alternative signaling, such as LCZ696 and phosphodiesterase-9 inhibitors. Additionally, understanding the role of adipokines in HFpEF may lead to new treatments. Identifying novel drug targets based on the shared underlying microvascular disease process may improve the quality of life and lifespan of those afflicted with both HFpEF and obesity or diabetes, or even prevent its occurrence.
No takes yet. Share an insight, caveat, or question.
Altara et al. (2017) conducted a review in Heart failure with preserved ejection fraction (HFpEF), obesity, and diabetes. Pharmacological and lifestyle interventions targeting microvascular inflammation was evaluated. Coronary microvascular inflammation with endothelial dysfunction is a common denominator among HFpEF, obesity, and diabetes, and targeting this shared underlying process may improve outcomes.
Synapse has enriched 10 related papers. Consider them for comparative context: